Leish-111f + MPL-SE

Leish-111f + MPL-SE is a recombinant protein subunit vaccine candidate developed by the Access to Advanced Health Institute (AAHI), formerly known as the Infectious Disease Research Institute (IDRI). The vaccine is designed for both the prevention and treatment of various forms of leishmaniasis, including visceral, cutaneous, and mucosal types. It consists of the **Leish-111f** (also known as Leish-F1) polyprotein, which is a fusion of three highly conserved *Leishmania* antigens: Thiol-specific antioxidant (TSA), *Leishmania major* Stress-Inducible Protein 1 (LmSTI1), and *Leishmania* Elongation Initiation Factor (LeIF). The vaccine is formulated with **MPL-SE**, an adjuvant system containing monophosphoryl lipid A (a Toll-like receptor 4 agonist) in a stable oil-in-water emulsion. This combination is intended to stimulate a robust Th1-type cell-mediated immune response, which is critical for the control of the intracellular *Leishmania* parasite.

Other names

LEISH-F1 + MPL-SELeish-111f vaccineLeish111f vaccineLeish 111f vaccineRecombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE